Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Interesting.
The position they last stated on the DoD order (per results) was
"The large sales opportunity for the product remains the fielding order of approximately 500 units over three years that the customer indicated in early 2020 - we expected the customer to decide on this procurement early in the new calendar year."
(Further at https://www.lse.co.uk/rns/GDR/final-results-tdum4ho1xqt1ow1.html)
So Walbrook are saying they haven't heard yet this year and speculating that it's unlikely because of that. If so, disappointing (though I'll wait to hear either way from DB on the 31st).
Starres I may be completely wrong but the impression I have is that the NICE guidance has literally just been waiting on the report being formally published (so that it can be cited, the research itself was already available). I.e. we should see it very shortly - it looked like it was marked up initially for 1 march, I think someone here contacted nice about it last few days and a date of 29th Mar was mentioned to them? Guess we'll see.
https://twitter.com/PALOH_Study/status/1505950401010540546?t=X09-MllxTY7fkRALqyTeXw&s=19
Study just published
https://twitter.com/genedriveplc/status/1505923634325565442?t=wqN6PLELSLS3RZ8F5WqGiA&s=19
No Gloria, they sneaked them in the back entrance of the hospitals without asking lol. Of course they have a contract ffs. And a long completed trial beforehand and NICE guidance due. And in PHE framework meaning other trusts can buy under that.
Dont think I'd be surprised if that one does come through guy. It was after all developed to US DoD specs with their funding to address their requirements and afaict showed up in a budget proposal last year. Definitely one to watch I'd have thought?
Hey no worries thanks Muminr, it felt like the broader market was asleep on that when it came out. Barely registered more widely. Glad some of us here took it on board! Yeah, agree, it was/is a great interview.